<DOC>
	<DOCNO>NCT00689390</DOCNO>
	<brief_summary>Study P05063 3-year long-term follow-up ( LTFU ) study participant previously treat boceprevir ( BOC ) narlaprevir ( NAR ) Phase 1 , 2 , 3 clinical study . Participants follow 3.5 year end participation treatment protocol document maintenance antiviral response ( sustained responder ) characterize long-term safety use therapeutic regimen . LTFU procedure include collection plasma sample measure Hepatitis C Virus ribonucleic acid ( HCV-RNA ) polymerase chain reaction ( PCR ) HCV sequence analysis . No drug therapy administer part study .</brief_summary>
	<brief_title>Three-year Follow-up Participants After Administration Boceprevir Narlaprevir Treatment Chronic Hepatitis C ( P05063 )</brief_title>
	<detailed_description>In Part 1 , participant previously participate one nine boceprevir study ( P03523 [ NCT00423670 ] , P03659 [ NCT00160251 ] , P04487 [ No NCT ] , P05101 [ NCT00708500 ] , P05216 [ NCT00705432 ] , P05411 [ NCT00959699 ] , P05514 [ NCT00910624 ] , P05685 [ NCT00845065 ] , P06086 [ NCT01023035 ] ) follow response . In Part 2 , participant previously participate one narlaprevir study ( P05104 [ NCT00797745 ] ) follow response .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Participant must willing give write informed consent able adhere visit schedule . Participant must receive least one dose boceprevir narlaprevir previous Phase 1 , 2 , 3 clinical study . Concurrent participation clinical study treatment chronic hepatitis C. Retreatment antiviral immunomodulatory drug chronic hepatitis C completion , discontinuation , SPRI Phase 1 , 2 , 3 clinical study participant previously participate . Any condition opinion Investigator would make participant unsuitable enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>